Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial-Reference-Cited by-同舟云学术

Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial

Published:2018-08 Issue:8 Volume:29 Page:1755-1762
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Arnedos M.^ORCID,Bayar M.A.,Cheaib B.,Scott V.,Bouakka I.,Valent A.,Adam J.,Leroux-Kozal V.,Marty V.,Rapinat A.,Mazouni C.,Sarfati B.,Bieche I.,Balleyguier C.,Gentien D.,Delaloge S.,Lacroix-Triki M.,Michiels S.^ORCID,Andre F.

Funder

Pfizer

Breast Cancer Research Foundation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/8/1755/25504966/mdy202.pdf

Reference13 articles.

1. Cell cycle, CDKs and cancer: a changing paradigm;Malumbres;Nat Rev Cancer,2009

2. Palbociclib in hormone-receptor-positive advanced breast cancer;Turner;N Engl J Med,2015

3. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC);Finn;N Engl J Med,2016

4. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival;Dowsett;Clin Cancer Res,2005

5. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group;Dowsett;J Natl Cancer Inst,2011

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?;Clinical Breast Cancer;2024-04

3. Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models;2024-03-26

4. Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond;Expert Review of Anticancer Therapy;2024-03-18

5. Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− metastatic breast cancer?;Annals of Oncology;2024-01